Please ensure Javascript is enabled for purposes of website accessibility

2 Innovative Growth Stocks to Buy for June

By Zhiyuan Sun - May 28, 2021 at 7:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Got cash? Consider these high-flying growth stocks.

Growth stocks are usually known to capitalize off short-term consumer trends. However, the best growth companies are the ones that set aside a portion of their revenues each quarter and reinvest back into innovation.

That kind of discipline is extremely hard to come by. Luckily, Roblox (RBLX -3.48%) and Novocure (NVCR -0.96%) are two fantastic companies that happen to possess it. Here's how the online game platform and the cancer-fighting biotech can add muscle to your portfolio. 

Salesperson handing out shopping item to customer.

Image source: Getty Images.

1. Roblox

Roblox is a do-it-yourself video game publishing platform with over 40 million games enjoyed by 42.1 million active users each day. Players are able to socialize with one another from around the world while having access to games on nearly all consoles, as well as spending its digital currency Robux to unlock better in-game experiences. 

During the first quarter of 2021, Roblox's revenue and free cash flow increased by 140% and 311% year over year, respectively, to $387 million and $421.1 million. What's more, these trends are reaching well into the second quarter. In April, the company's sales increased by 138% to $144 million. 

A big reason behind Roblox's success is its commitment to innovation and its clients. The firm pays out as much as 31% of its sales to game developers. In addition, another 24% of revenue went into developing the platform infrastructure, as well as moderation to maintain trust and safety in the community. 

Right now, Roblox stock may seem a little expensive at 21.3 times estimated fiscal 2021 sales. However, keep in mind that the company is growing its sales by upwards of triple-digit percentages, so it is well worth the premium. Due to its high-value proposition, scalable business model, and consistent reinvestment back into its platform, Roblox is one of the top tech stocks to buy now. 

2. Novocure

Novocure is at the forefront of using innovative technology to combat cancer. Its flagship product, Optune, is a wearable and portable device that delivers alternating electric fields (Tumor Treating Fields, or TTFs) to disrupt the ability of cancer cells to multiply. Researchers carefully tailored the frequency so that it would only destroy malignant cells and not healthy ones.

The device is currently indicated for the treatment of glioblastoma (a deadly form of brain cancer) and mesothelioma. In Q1 2021, Novocure's revenue grew by 32% annually to $134.7 million. Simultaneously, the company's operating income less noncash items (EBITDA) increased by 40% to $21.415 million. 

There are now 3,454 active patients receiving care via Optune, and that number is about to rise sharply. On May 18, Novocure announced that the U.S. Food and Drug Administration agreed to reduce the number of patients enrolled in a phase 3 trial to test the efficacy of TTFs in targeting advanced stage non-small cell lung cancer (NSCLC). According to an independent committee monitoring the study: "... it is likely unnecessary and possibly unethical for patients randomized to the control arm of the trial to continue accrual according to the original protocol."

It can only be considered unethical for patients to receive the control treatment when the experimental therapy has a huge clinical benefit. Hence, the approval of TTFs for NSCLC is almost guaranteed at this point, especially considering that there was no evidence of toxicity in the study. Keep in mind that this is a market forecasted to reach $48 billion by 2026.

Aside from that, Novocure is also investigating TTFs for targeting brain metastasis, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer. Like Roblox, the company dedicates much of its revenue (close to 34%) to research and development so that its growth is sustainable for the long term. Overall, it is a well-rounded healthcare stock to consider for one's portfolio. 

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Novocure. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NovoCure Stock Quote
NovoCure
NVCR
$82.25 (-0.96%) $0.80
Roblox Corporation Stock Quote
Roblox Corporation
RBLX
$46.10 (-3.48%) $-1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.